期刊论文详细信息
Frontiers in Rehabilitation Sciences
Combining spinal neuromodulation and activity based neurorehabilitation therapy improves sensorimotor function in cerebral palsy
Rehabilitation Sciences
Yousef Shirkhani1  V. Reggie Edgerton2  Parag Gad3  Kristin Girshin4  Rahul Sachdeva5 
[1] GirshinPT, Rancho Cucamunga, CA, United States;Rancho Research Institute, Downey, CA, United States;USC Neurorestoration Center, University of Southern California, Los Angeles, CA, United States;Institut Guttmann, Hospital de Neurorehabilitació, Institut Universitari Adscrit a la Universitat Autònoma de Barcelona, Barcelona, Spain;SpineX Inc., Los Angeles, CA, United States;SpineX Inc., Los Angeles, CA, United States;GirshinPT, Rancho Cucamunga, CA, United States;SpineX Inc., Los Angeles, CA, United States;International Collaboration on Repair Discoveries (ICORD), Department of Medicine, University of British Columbia, Vancouver, BC, Canada;
关键词: spinal cord neuromodulation;    noninvasive stimulation;    cerebral palsy;    sensorimotor function;    spasticity;   
DOI  :  10.3389/fresc.2023.1216281
 received in 2023-05-03, accepted in 2023-07-10,  发布年份 2023
来源: Frontiers
PDF
【 摘 要 】

Motor dysfunction in individuals with cerebral palsy (CP) such as the inability to initiate voluntary movements, walking with compensatory movement patterns, and debilitating spasticity is due to the aberrant neural connectivity between the brain and spinal cord. We tested the efficacy of noninvasive spinal cord neuromodulation (SCiP™, SpineX Inc.) with activity-based neurorehabilitation therapy (ABNT) in improving the sensorimotor function in six children with CP. Children received 8 weeks of either SCiP™ or sham therapy with ABNT (n = 3 per group). At the end of 8 weeks, all participants received 8 weeks of SCiP™ therapy with ABNT. Follow up assessments were done at week 26 (10 weeks after the last therapy session). Sensorimotor function was measured by the Gross Motor Function Measure 88 (GMFM88) test. We observed minimal change in sham group (mean 6% improvement), however, eight weeks of SCiP™ therapy with ABNT resulted in statistically and clinically relevant improvement in GMFM88 scores (mean 23% increase from baseline). We also observed reduced scores on the modified Ashworth scale only with SCiP™ therapy (−11% vs. +5.53% with sham). Similar improvements were observed in sham group but only after the cross over to SCiP™ therapy group at the end of the first eight weeks. Finally, sixteen weeks of SCiP™ therapy with ABNT resulted in further improvement of GMFM88 score. The improvement in GMFM88 scores were maintained at week 26 (10 weeks after the end of therapy), suggesting a sustained effect of SCiP™ therapy.

【 授权许可】

Unknown   
© 2023 Sachdeva, Girshin, Shirkhani, Gad and Edgerton.

【 预 览 】
附件列表
Files Size Format View
RO202310109712677ZK.pdf 862KB PDF download
  文献评价指标  
  下载次数:0次 浏览次数:0次